Share price of Bangalore-based biotechnology firm, Biocon Ltd, rose 3.27 per cent to Rs 341.50 at the end of today's trading session at the Bombay Stock Exchange (BSE).
This despite the company's stated stand of no possible deal with Pfizer in the near future.
The company’s share price touched a 52-weeks high on Monday on speculation that the global drug major, Pfizer, may buy stake or strike a marketing deal with the company.
However, it has been strongly denied by Biocon. “We don’t want to comment on speculation,” a company spokesperson said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app